87 results
The overall study objective is to evaluate the safety and efficacy of NiCord®: single ex-vivo expanded cord blood unit transplantation in patients with hematological malignancies following myeloablative therapy.
To evaluate the safety of an autologous cellular collagen hydrogel-based skin graft (denovoDerm) in patients with skin defects that require definitive therapeutic coverage. DenovoDerm can be transplanted together with an STSG to cover a full…
To investigate feasibility, safety and toxicity as well as immune-response of an allogeneic tumor cell lysate (PheraLys) loaded onto autologous dendritic cells (MesoPher) in resected pancreatic cancer patients who received adjuvant standard of care…
In this phase I/II clinical study will assess the safety, effectiveness and homing of asCTMP, namely autologous mesoangioblasts, that will be injected 3x intra-arterially in right lower leg via catheter in 5 indivuals that carry the m.3243A>G…
To evaluate the safety and toxicity of ACT and low-dose IFN-alpha plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that do not result in treatment termination are considered acceptable for…
The main objective is to objectify if the injection of SVF influences the pain of the TMJ during movement. Secondary objectives are pain during rest, maximum mouth opening, and function evaluation.
The objective of the present trial is to investigate the safety of an allogenic tumor cell lysate loaded onto autologuous dendritic cells (AlloDen) in patients with malignant mesothelioma (MM). Heretoo we will perform a phase I study with a…
Primary ObjectiveTo demonstrate that the effectiveness of the NOVOCART® 3D plus autologouschondrocyte transplantation system is superior to microfracture for the treatment ofarticular cartilage defects of the knee by demonstrating superiority of the…
The main objective is assessment of safety and feasibility of intravenous administration of autologous, in vitro expanded, mesenchymal stem cells in patients with pulmonary arterial hypertension due to systemic sclerosis. The secondary objective is…
To determine the efficacy and the safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of non-infected hypotrophic non-union fractures of long bones.
This is an interventional study and the primary objective is the immunogenicity of combined pDC and myDC vaccination. The secondary objectives are the biodistribution, the safety, quality of life and overall survival.
To show immunologic efficacy of tumor-peptide loaded natural DC in mCRPC patients. Further we will demonstrate that natural DC vaccinations are safe, feasible and clinically effective. Also the therapy effect on quality of life will be studied.
The study will evaluate the injection of AMDC for Urinary Sphincter Repair (USR) compared to a placebo dose, with the hypothesis that one or two treatments of AMDC is statistically superior to placebo at 12 months following the initial treatment.
Determine the safety and efficacy of Tiscover compared to AS210 (acellular donor dermis, construct Tiscover is cultured on) for the treatment of chronic, therapy resistant (arterio-) veneus leg/foot ulcers in an out patient setting.
The primary objective is the safety and feasibility of CEA/frameshift derived neopeptide loaded DC in patient with MSI-positive colorectal cancer and persons who are known to be carrier of a germline MMR-gene mutation with no signs of disease yet.…
A 6-month study of efficacy and safety comparing concentration-controlled Certican® with MSCs to Certican® with standard tacrolimus in renal transplant recipients
Primary: 1 to test the safety and feasibility of autologous MSC therapy in HLA-DR mismatched patients with SCR in the renal biopsy 4 weeks after renal transplantation.Secondary1 To assess histologic changes before and after MSC treatment.2 To…
The primary goal is to show the capability of monocyte-derived DC after RNA electroporation for melanoma antigens to induce an immune response.The secondary objective is to show clinical response.
To test the safety and feasibility of intravenous administration of autologous BM-MSC after one-sided LVRS and prior to a second LVRS procedure for patients with end-stage pulmonary emphysema and to compare with historic lung function data of a…
We expect to finalize the current phase I study by the May 2008 demonstrating that injection of tumor lysate-pulsed autologous DCs injected in patients with MM after chemotherapy is safe and well tolerated with induction of immune responses. New…